Emanuele D. D'amico-Amico
Foggia, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Cognitive and structural brain changes in ofatumumab-treated multiple sclerosis: A longitudinal study.
Journal: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
Published: February 24, 2026
Multidomain Fatigue, Cognitive, and Quality of Life Observations in Generalized Myasthenia Gravis Under Ravulizumab: A Case Series.
Journal: Neurology and therapy
Published: February 08, 2026
Transitioning from intravenous to subcutaneous ocrelizumab in a high-volume infusion center: A time-and-motion-informed capacity and service-flow analysis.
Journal: Multiple sclerosis and related disorders
Published: December 09, 2025
Evaluating Cognitive Outcomes in Multiple Sclerosis: Real-World Impact of Ozanimod on Processing Speed Using BICAMS.
Journal: Neurology and therapy
Published: February 08, 2025
Multiple sclerosis from onset to secondary progression: a 30-year Italian register study.
Journal: Journal of neurology, neurosurgery, and psychiatry
Published: February 02, 2025
Unraveling the inflammation-degeneration tangle in early MS: preliminary insights from ferritin, neurogranin, TREM2, and retinal ganglion cell layer.
Journal: Journal of neurology
Published: August 22, 2024
Siponimod following Alemtuzumab in secondary progressive MS: investigating sequential therapy-A case series.
Journal: Multiple sclerosis and related disorders
Published: June 09, 2024
Ocrelizumab and ofatumumab comparison: an Italian real-world propensity score matched study.
Journal: Journal of neurology
Published: January 15, 2024
Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic.
Journal: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
Published: August 10, 2022
MicroRNAs 181a and 125a are highly expressed in naïve RRMS: a pilot case-control study.
Journal: Journal of neurology
Published: July 14, 2022
Real world comparison of teriflunomide and dimethyl fumarate in naïve relapsing multiple sclerosis patients: Evidence from the Italian MS register.
Journal: Multiple sclerosis and related disorders
Published: December 07, 2021
Showing 1-11 of 11
Last Updated: 09/26/2026